A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (UBeyoNDU)

Administered By

Awarded By

Contributors

Start/End

  • June 15, 2017 - February 8, 2018